Core Points - A class action lawsuit has been filed against Zenas BioPharma, Inc. for alleged securities fraud and unlawful business practices [2][4] - Investors who purchased Zenas securities during its initial public offering (IPO) are encouraged to join the class action by contacting Pomerantz LLP [1][2] - Zenas conducted its IPO on September 13, 2024, selling approximately 13.235 million shares at $17.00 per share, but its stock price has significantly declined since then [4] Company Information - Zenas BioPharma, Inc. is facing legal scrutiny due to claims of misleading statements regarding its financial stability post-IPO [2][4] - The company stated it could fund operations for "at least" the next twelve months, contrary to earlier claims of twenty-four months in its IPO registration [4] Legal Context - The deadline for investors to request appointment as Lead Plaintiff in the class action is June 16, 2025 [2] - Pomerantz LLP is recognized for its expertise in corporate and securities class litigation, having a long history of advocating for victims of securities fraud [5]
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Zenas BioPharma, Inc. of Class Action Lawsuit and Upcoming Deadlines – ZBIO